AbbVie Inc (ABBV)vsImmunocore Holdings Ltd (IMCR)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
IMCR
Immunocore Holdings Ltd
$27.92
-3.02%
HEALTHCARE · Cap: $1.42B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 15189% more annual revenue ($61.16B vs $400.02M). ABBV leads profitability with a 6.9% profit margin vs -8.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
IMCR
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
+2.5%
Fair Value
$33.76
Current Price
$27.92
$5.84 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Earnings expanding 822.0% YoY
Revenue surging 24.3% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 0.0%
ROE of -9.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : IMCR
The strongest argument for IMCR centers on EPS Growth, Revenue Growth. Revenue growth of 24.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : IMCR
The primary concerns for IMCR are Market Cap, Operating Margin, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while IMCR is a growth play — different risk/reward profiles.
IMCR carries more volatility with a beta of 0.83 — expect wider price swings.
IMCR is growing revenue faster at 24.3% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Immunocore Holdings Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?